anti-cancer agent

CFT7455 (Cemsidomide) is an anti-cancer agent showing high affinity to the cereblon E3 ligase with a Kd of 0.9 nM. CFT7455 is an orally active degrader of zinc finger transcription factors Ikaros (IKZF1), and Aiolos (IKZF3).

Triglycidyl isocyanurate (Teroxirone) is a triazene triepoxide with antineoplastic and antiangiogenic activity. It inhibits growth of human non-small cell lung cancer cells by activating p53. Triglycidyl isocyanurate alkylates and cross-links DNA, thereby inhibiting DNA replication. It induces cell apoptosis and can be used for cancer research[1][2]. Triglycidyl isocyanurate is also used in various polyester powder coatings in the metal finishing industry.

Tirapazamine (Win59075) is a potent cytotoxic agent under hypoxic conditions, can induce apoptosis by inducing breaks in single and double-stranded DNA, as well as chromosomal breaks. The compound sensitizes cells to other ionizing radiation and other cytotoxic agents like cisplatin.

Anticancer agent 3 (Compound 4) is an anticancer agent.

(S)-5-chloro-N-(1-((4-chlorophenyl)amino)-1-oxo-3-phenylpropan-2-yl)-2-hydroxybenzamide has antifungal and tuberculostatic activities.

Anticancer agent 110 is an anticancer compound with cytotoxic, antitumor, and antileukemic activity that triggers DNA damage and apoptosis and is used in the study of chronic granulocytic leukemia.

Anticancer agent 46 is a potent anti-cancer agent, showing anti-proliferative activity in cellular assays, with an IC50 of 0.986 μM against MGC803 cells.

Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) and a HER2-targeted cytotoxic agent, consisting of an anti-HER2 monoclonal antibody conjugated to MMAE via a cleavable linker, used for the treatment of HER2-expressing solid tumors including gastric cancer, breast cancer, and urothelial carcinoma.

Ponsegromab (PF 06946860) is a selective and potent humanized anti-GDF15 antibody inhibitor with IC₅₀ values of 0.123 nM, 0.053 nM, and 0.102 nM for human, rhesus macaque, and mouse targets, respectively. Ponsegromab exhibits anti-cachexia activity by binding to GDF15 to prevent its interaction with GFRAL, thereby disrupting GDF15/GFRAL-mediated signaling. Ponsegromab possesses potential anticancer activity and may be used to treat cancer patients with cancer anorexia-cachexia syndrome. Ponsegromab acts as a chemopreparative agent, increasing intracellular reactive oxygen species levels and reducing glutathione levels.

Anticanceragent 260 (Compound 3g/4d) is an orally effective anticancer agent that inhibits the proliferation of cancer cells HCT-116, MIA-PaCa2, and MDA-MB231, with IC50 values of 98.7, 81.0, and 77.2 µg/mL, respectively. It also promotes ulcer formation and lipid peroxidation, and exhibits anti-inflammatory and analgesic activities.

Anticancer agent 7 (Example 5) is a potent anti-cancer compound with an IC50 value of 5 μM against H1650 lung cancer cells.

Compound 12, also known as Anticancer agent 68, functions as an anti-cancer agent by arresting cells at the G2/M phase and inducing programmed cell death. Moreover, it promotes tumor suppression by activating p53 and PTEN [1].

Anticancer agent 56 (compound 4d) is a powerful anti-cancer compound with favorable drug-like properties, showing significant anticancer activity against multiple cancer cell lines with an IC50 value of less than 3 μM. It exerts its effects by causing cell cycle arrest at the G2/M phase and activating the mitochondrial apoptosis pathway, inducing the accumulation of reactive oxygen species (ROS), upregulating BAX, downregulating Bcl-2, and triggering the activation of caspases 3, 7, and 9 [1].

Anticancer agent 78 has anti-aromatase activity (IC50=0.9 μM). Anticancer agent 78 is an effective anticancer agent, showing cytotoxicity. Anticancer agent 78 has research potential in breast cancer.

Anticancer agent 79 (compound 3d) is an anticancer compound with good anti-breast cancer activity, exhibiting cytotoxic activity in T47-D cells (IC50= 13.64 ± 0.26 μM).

Anticancer agent 36 (compound 11) is a potent anti-microbial and anti-cancer agent, a sulfonylurea derivative. anticancer agent 36 inhibits the microbial growth of Bacillus mycoides, Escherichia coli and Candida albicans (MIC: 0.156 - 0.039 mg/mL). Anticancer agent 36 inhibited the growth of A549 cells (IC50: 19.7 μg/mL), PC3 cells (IC50: 11.9 μg/mL).

Anticancer agent 34 (compound 9) is a sulfonylurea derivative and a potent anti-microbial and anti-cancer agent. anticancer agent 34 showed inhibition of microbial growth of Mycobacterium, Escherichia coli and Candida albicans (MIC: 0.039-0.156 mg/ml). Anticancer agent 34 inhibited the growth of A549 cells (IC50: 8.4 μg/ml), PC3 cells (IC50: 7.8 μg/ml).

Anticancer agent 62 is an effective anticancer agent. anticancer agent 62 exhibited anti-proliferative effects on HepG2, Bel-7402 and MCF-7 cancer cells with IC50 values of 0.019, 0.060 and 0.016 μM, respectively. anticancer agent 62 was able to inhibit tumor growth.

Anticancer agent 76 (Compound CT2-3) significantly inhibits proliferation, induces cell cycle arrest, ROS production, and apoptosis in human NSCLC cells.

Anticancer Agent is a potent anti-cancer agent that exhibits anti-cancer effects by inhibiting cell viability and cell migration in a dose-dependent manner and inducing apoptosis.Anticancer Agent has potential for prostate and breast cancer research.

Anticancer agent 100, a tetracaine derivative, exhibits anti-cancer activity and is applied in cancer research.

Anticancer agent 66, a ciprofloxacin analog, functions as an anti-cancer agent by inducing apoptosis and elevating the sub-G1 cell population in MCF-7 cells.

Anticancer Agent 102, a tetracaine derivative, exhibits anti-cancer activity by inducing apoptosis [1].

Anticancer Agent 157 (compound 15) is a nitric oxide (NO) inhibitor with IC50 values of 0.62 μg/mL, exhibiting both anti-inflammatory and anticancer effects. It interacts with inducible NO synthase (iNOS) and caspase 8, which facilitates apoptosis through nuclear fragmentation and chromatin condensation. Additionally, Anticancer Agent 157 effectively inhibits HT29 colon cancer cells (IC50 =2.45 μg/mL), Hep-G2 liver cancer cells (IC50 =3.25 μg/mL), and B16-F10 murine melanoma cells (IC50 =3.84 μg/mL) [1].